NVAX Valuation

Novavax Inc

Add to Watchlist

Advanced Chart

7.470

-0.17(-2.225%)1D

Overview
Forecast
Valuation
Earnings

NVAX Relative Valuation

NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVAX is overvalued; if below, it's undervalued.

Historical Valuation

Novavax Inc (NVAX) is now in the Fair zone, suggesting that its current forward PS ratio of 2.47 is considered Fairly compared with the five-year average of 0.84. The fair price of Novavax Inc (NVAX) is between 6.47 to 16.74 according to relative valuation methord.

Relative Value

Fair Zone

6.47-16.74

Current Price：7.47

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-15.99

P/B

Median3y

-3.18

Median5y

9.02

-15.89

FCF Yield

Median3y

-57.74

Median5y

-34.46

Competitors Valuation Multiple

The average P/S ratio for NVAX's competitors is 8.04, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX) exhibits a P/S ratio of 2.47, which is -69.29% above the industry average. Given its robust revenue growth of 610.30%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap